News

Good News | HYBIO Pharmaceutical Completes Official NMPA Registration of Semaglutide API

Recently, a public disclosure by China’s National Medical Products Administration (NMPA) indicated that Hybio Pharmaceutical (Wuhan) Co., Ltd. has completed the official registration of its semaglutide active pharmaceutical ingredient (API) (Registrati...

Good News | Hybio Pharmaceutical Completes Official NMPA Registration for Tirzepatide API

Recently, the National Medical Products Administration (NMPA) information platform published an update showing that Hybio Pharmaceutical (Wuhan) Co., Ltd. has completed the official registration for its Tirzepatide active pharmaceutical ingredient (API) (R...

Hybio Pharmaceutical and Dr. Reddy’s Sign non-binding strategic cooperation term sheet on Peptide APIs to Advance Global Peptide Collaboration

December 25 — Hybio Pharmaceutical and Dr. Reddy’s Laboratories Limited (referred to as “Dr. Reddy’s”), a global pharmaceutical company, held a signing ceremony in Beijing, where the two parties formally executed a non-binding...

HYBIO Pharmaceutical Takes a Strategic Minority Stake in iCarbonX to Strengthen AI-Peptide R&D and Industrialization Collaboration

HYBIO Pharmaceutical Co., Ltd. (“HYBIO Pharmaceutical”) has entered into a strategic investment partnership with Shenzhen iCarbonX Intelligent Technology Co., Ltd. (“iCarbonX”). Under the agreement, HYBIO Pharmaceutical will invest RM...

Hybio Pharmaceutical’s Longhua Headquarters R&D Center Laboratory Passes FDA Inspection Again with “Zero Deficiencies”

On December 5, 2025, the laboratory at the R&D Center of Hybio Pharmaceutical’s Longhua Headquarters successfully passed an on-site inspection by the U.S. Food and Drug Administration (FDA) with a “zero-deficiency” result—receiving ...

Dr. Reddy’s Global CEO Leads Delegation to Hybio, Mapping Out International Peptide Partnership

Hybio Pharmaceutical and Institute of Process Engineering, Chinese Academy of Sciences Enter into Strategic Cooperation to Jointly Establish "Innovation Consortium for Industrial Transformation of Hig

On August 20,2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and the Institute of Process Engineering, Chinese Academy of Sciences (referred to as "IPE-CAS") officially signed a strategic cooperation agreement to jointly build the "Innovation Consortium for Industrial Transformation of High-End Peptide Sustained-Release Preparations". 

Hybio Pharmaceutical and Sunshine Mandi Pharmaceutical Sign a Series of Commercial Agreements, Accelerating the Progress of Weight-Loss Drugs Across the Board

Beijing, August 19, 2025. Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (referred to as "Sunshine Mandi") officially signed a series of commercial documents in Beijing today

Hybio Pharmaceutical and KuCoin Join Forces to Pioneer China’s First RWA Pilot in Innovative Drug Development

On August 4, 2025, Hybio Pharmaceutical and KuCoin, a world-leading digital asset platform, formally signed a strategic cooperation letter of intent. Both parties plan to jointly explore and advance the first RWA (Real World Asset) tokenization pilot project in Hong Kong with "future income rights from innovative drug R&D" as the underlying asset, originating from the Chinese mainland.

Hybio Pharmaceutical and BrightGene Pharmaceutical Enter into Strategic Cooperation to Safeguard Overseas Supply Chains for Innovative Drugs

Hybio Pharmaceutical and iCarbonX Intelligent Peptide Deepen Strategic Cooperation, Signing Two Agreements on Innovative Drug CRDMO Services and Strategic Investment

Academician Ma Guanghui of the Chinese Academy of Sciences and His Delegation Visited Hybio Pharmaceutical to Explore the Development of Long-Acting High-Effect Innovative Peptide Formulations

Hybio Pharmaceutical and iCarbonX-Peptide Sign Joint Development Agreement for GLP-1R/GIPR/GCGR Triple Agonist Peptide Innovative Drug

On May 9, 2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (referred to as "Hybio Pharmaceutical") and Shenzhen iCarbonX Intelligent Peptide Pharmaceutical Technology Co., Ltd. (referred to as "iCarbonX Intelligent Peptide") formally signed a joint development agreement for GLP-1R/GIPR/GCGR triple agonist peptide innovative drugs and held a grand signing ceremony.

Hybio Pharmaceutical, Hybio Health, and BMC Medical Sign Strategic Cooperation Agreement to Build a New Ecosystem for Sleep Health Management

On May 12, Hybio Pharmaceutical, Hybio Health, and BMC Medical signed a strategic cooperation agreement. The three parties will engage in comprehensive strategic cooperation in the field of sleep health across multiple dimensions, including scenario application, technology synergy, scientific research collaboration, market synergy, and user reach.

Hybio Pharmaceutical and Sinopharm CNCM Sign Strategic Cooperation Agreement to Explore New Paths for Innovative Drug R&D